Cited by 1,566Adrenal and Paraganglionic TumorsPituitary Gland Disorders and TreatmentsAdrenal Hormones and Disorders

Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors

Open access
Fassnacht, Martin, Arlt, Wiebke, Bancos, Irina, Dralle, Henning, Newell-Price, John, Sahdev, Anju, Tabarin, Antoine, Terzolo, Massimo +2 more·2016·European Journal of Endocrinology

Abstract

By definition, an adrenal incidentaloma is an asymptomatic adrenal mass detected on imaging not performed for suspected adrenal disease. In most cases, adrenal incidentalomas are nonfunctioning adrenocortical adenomas, but may also represent conditions requiring therapeutic intervention (e.g. adrenocortical carcinoma, pheochromocytoma, hormone-producing adenoma or metastasis). The purpose of this guideline is to provide clinicians with best possible evidence-based recommendations for clinical management of patients with adrenal incidentalomas based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. We predefined four main clinical questions crucial for the management of adrenal incidentaloma patients, addressing these four with systematic literature searches: (A) How to assess risk of malignancy?; (B) How to define and manage low-level autonomous cortisol secretion, formerly called ‘subclinical’ Cushing’s syndrome?; (C) Who should have surgical treatment and how should it be performed?; (D) What follow-up is indicated if the adrenal incidentaloma is not surgically removed? Selected recommendations: (i) At the time of initial detection of an adrenal mass establishing whether the mass is benign or malignant is an important aim to avoid cumbersome and expensive follow-up imaging in those with benign disease. (ii) To exclude cortisol excess, a 1mg overnight dexamethasone suppression test should be performed (applying a cut-off value of serum cortisol ≤50nmol/L (1.8µg/dL)). (iii) For patients without clinical signs of overt Cushing’s syndrome but serum cortisol levels post 1mg dexamethasone >138nmol/L (>5µg/dL), we propose the term ‘autonomous cortisol secretion’. (iv) All patients with ‘(possible) autonomous cortisol’ secretion should be screened for hypertension and type 2 diabetes mellitus, to ensure these are appropriately treated. (v) Surgical treatment should be considered in an individualized approach in patients with ‘autonomous cortisol secretion’ who also have comorbidities that are potentially related to cortisol excess. (vi) In principle, the appropriateness of surgical intervention should be guided by the likelihood of malignancy, the presence and degree of hormone excess, age, general health and patient preference. (vii) Surgery is not usually indicated in patients with an asymptomatic, nonfunctioning unilateral adrenal mass and obvious benign features on imaging studies. We provide guidance on which surgical approach should be considered for adrenal masses with radiological findings suspicious of malignancy. Furthermore, we offer recommendations for the follow-up of patients with adrenal incidentaloma who do not undergo adrenal surgery, for those with bilateral incidentalomas, for patients with extra-adrenal malignancy and adrenal masses and for young and elderly patients with adrenal incidentalomas

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/eje-16-0467

Cites

228 of 228 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Most studies have found that late-night salivary cortisol (LNSC), regardless of assay method, has poor sensitivity in patients with mild cortisol excess (formerly subclinical Cushing syndrome).

    “most studies have found that LNSC (regardless of assay method) has a poor sensitivity in patients with mild cortisol excess (formerly known as subclinical CS) [20, 56, 62-76]”

    From Prospective Evaluation of Late-Night Salivary Cortisol and Cortisone by EIA and LC-MS/MS in Suspected Cushing Syndrome (2020) · cites this paper as [64]

    The Reasoning section says that a few studies suggest poor performance of late-night salivary cortisol in patients with adrenal incidentalomas. It does not say that most studies found poor sensitivity, or that the finding holds regardless of assay method; a response to comment #28 describes the data as conflicting. Page numbers are unavailable in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Diagnosing CS and ACS in patients with adrenal incidentaloma remains a challenge, partly due to a lack of biochemical tests with high diagnostic accuracy.

    “Diagnosing Cushing’s syndrome (CS) and autonomous cortisol secretion (ACS) in patients with adrenal incidentaloma remains a challenge, partly due to a lack of biochemical tests with high diagnostic accuracy (1, 2).”
  • In general, p-cortisol following DST <50 nmol/L was considered to exclude hypercortisolism.

    “In general, p-cortisol following DST <50 nmol/L was considered to exclude hypercortisolism, while values >138 nmol/L were considered to be highly suggestive for hypercortisolism (1, 2).”
  • For patients with adrenal incidentaloma, DST is the most commonly recommended first-line screening test for ACS.

    “For patients with adrenal incidentaloma, DST is the most commonly recommended first-line screening test for ACS (1–5).”
  • In general, p-cortisol following DST >138 nmol/L was considered highly suggestive for hypercortisolism.

    “In general, p-cortisol following DST <50 nmol/L was considered to exclude hypercortisolism, while values >138 nmol/L were considered to be highly suggestive for hypercortisolism (1, 2).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 5

  1. [96]96. ESE and ENSAT guideline on adrenal incidentaloma 96. Boraschi P, Braccini G, Gigoni R, Perri G, Campatelli A, Di Vito A & Bonadio AG. Diagnosis of adrenal adenoma: value of central spot of high-intensity hyperintense rim sign and homogeneous isointensity to liver on gadolinium-enhanced fat-suppressed spin-echo MR images. Journal of magnetic resonance imaging : JMRI 1999 9 304-310.
  2. [97]97. Chung JJ, Semelka RC & Martin DR. Adrenal adenomas: characteristic postgadolinium capillary blush on dynamic MR imaging. Journal of magnetic resonance imaging : JMRI 2001 13 242-248.
  3. [138]138. Fagour C, Bardet S, Rohmer V, Arimone Y, Lecomte P, Valli N & Tabarin A. Usefulness of adrenal scintigraphy in the follow-up of adrenocortical incidentalomas: a prospective multicenter study. European Journal of Endocrinology 2009 160 257-264. 162.
  4. [181]181. High prevalence of autonomous aldosterone secretion among patients w essential hypertension. Aggeliki Gouli, Gregory Kaltsas, Anastasia Tzonou, Ath Markou, Ioannis I. Androulakis, Despina Ragkou, Kyriakos Vamvakidis, Georg Zografos, Georgios Kontogeorgos, George P. Chrousos and Georgios Piaditis. E J Clin Invest 2011; 41 (11): 1227-1236
  5. [182]182. Primary aldosteronism in hypertensive patients: clinical implications a target therapy. Labrini Papanastasiou, Athina Markou, Theodora Pappa, Agge Gouli, Panagiotis Tsounas, Stelios Fountoulakis, Theodora Kounadi, Vas Tsiama, Aikaterini Dasou, Alexandros Gryparis, Christianna Samara, Geo Zografos, Gregory Kaltsas, George Chrousos and George Piaditis. Eur J C Invest 2014; 44 (8): 697-706

Cited by

Sorted by citations

Authors
Fassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M.
Affiliations
  • University of Würzburg (DE)
  • University of Birmingham (GB)
  • Mayo Clinic (US)
  • Martin Luther University Halle-Wittenberg (DE)
  • Royal Hallamshire Hospital (GB)
  • St Bartholomew's Hospital (GB)
  • Inserm (FR)
  • University of Turin (IT)
  • Evangelismos Hospital (GR)
  • Aarhus University (DK)
Corresponding author
Fassnacht, Martin
Venue
European Journal of Endocrinology
Published
2016-08
Volume
175
Issue
2
Pages
G1-G34
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2469640494
Cited by
1,566
References
228
Citations by year
2026: 69 · 2025: 116 · 2024: 126 · 2023: 199 · 2022: 265 · 2021: 209 · 2020: 190 · 2019: 137 · 2018: 139 · 2017: 94 · 2016: 17 · 2015: 2
FWCI
142.90
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • European Journal of Endocrinology (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Scopus (Elsevier) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion)
Funders
  • European Society of Endocrinology
  • Cancer Research UK (15622)
  • European Science Foundation
Topics
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
adrenal incidentaloma, adrenal adenoma, adrenocortical carcinoma, pheochromocytoma, autonomous cortisol secretion, subclinical Cushing's syndrome, dexamethasone suppression test, cancer risk, adrenalectomy, follow-up imaging, hypertension, type 2 diabetes, adrenal metastasis
MeSH terms
Adrenal Gland Neoplasms, Humans, Hydrocortisone, Incidental Findings

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review